BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kao D, Wong K, Franz R, Cochrane K, Sherriff K, Chui L, Lloyd C, Roach B, Bai AD, Petrof EO, Allen-Vercoe E. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol 2021;6:282-91. [PMID: 33631102 DOI: 10.1016/S2468-1253(21)00007-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Mccoubrey LE, Elbadawi M, Basit AW. Current clinical translation of microbiome medicines. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.02.001] [Reference Citation Analysis]
2 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
3 Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes 2022;14:2038856. [PMID: 35230889 DOI: 10.1080/19490976.2022.2038856] [Reference Citation Analysis]
4 Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211017725. [PMID: 34104212 DOI: 10.1177/17562848211017725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
6 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Khanna S. A defined microbiome therapeutic prevents recurrent Clostridioides difficile. Lancet Gastroenterol Hepatol 2021;6:255-6. [PMID: 33631103 DOI: 10.1016/S2468-1253(21)00011-X] [Reference Citation Analysis]
8 Oliphant K, Ali M, D'Souza M, Hughes PD, Sulakhe D, Wang AZ, Xie B, Yeasin R, Msall ME, Andrews B, Claud EC. Bacteroidota and Lachnospiraceae integration into the gut microbiome at key time points in early life are linked to infant neurodevelopment. Gut Microbes 2021;13:1997560. [PMID: 34839801 DOI: 10.1080/19490976.2021.1997560] [Reference Citation Analysis]
9 Liu Y, Budylowski P, Dong S, Li Z, Goroshko S, Leung LYT, Grunebaum E, Campisi P, Propst EJ, Wolter NE, Rini JM, Zia A, Ostrowski M, Ehrhardt GRA. SARS-CoV-2-Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals. J Immunol 2021;207:2581-8. [PMID: 34607939 DOI: 10.4049/jimmunol.2100606] [Reference Citation Analysis]
10 Kazemian N, Kao D, Pakpour S. Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic. Int J Mol Sci 2021;22:3004. [PMID: 33809421 DOI: 10.3390/ijms22063004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Sorbara MT, Pamer EG. Microbiome-based therapeutics. Nat Rev Microbiol 2022. [PMID: 34992261 DOI: 10.1038/s41579-021-00667-9] [Reference Citation Analysis]
12 Aggarwala V, Mogno I, Li Z, Yang C, Britton GJ, Chen-Liaw A, Mitcham J, Bongers G, Gevers D, Clemente JC, Colombel JF, Grinspan A, Faith J. Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nat Microbiol 2021;6:1309-18. [PMID: 34580445 DOI: 10.1038/s41564-021-00966-0] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]